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The term "biotechnology" is ambiguous, and the lack of
consensus on what it means has been the source of much con-
fusion. One of the broader definitions is "the application of
biological systems and organisms to technical and industrial
processes."' This definition includes processes as diverse
as fish farming, beer fermentation, and recombinant DNA
(rDNA), or "gene-splicing", techniques. Recombinant DNA
is really an extension of the classical breeding techniques
which have been used by plant and animal geneticists for de-
cades. Classical breeding techniques involve the selective
breeding of plants or animals, with the intent of producing
offspring with the desired trait. Recombinant DNA technol-
ogy furthers the specificity of the selection process by making
it possible to add or delete specific genetic traits, permitting
greater certainty that particular characteristics will be repre-
sented in the offspring.
The ethics and safety of biotechnology have been de-
bated since scientists first began to investigate the new tech-
nology in the early 1970s. The concern expressed by molecu-
lar biologists about the safety of biotechnology research led
first to a moratorium on certain research and then to the
Asilomar Conference in 1974, a gathering of scientists spon-
sored by the United States government to discuss safety and
ethical questions. As a result of this conference, the morato-
rium was lifted for most experiments and guidelines for
conducting rDNA research were published by the National
* General Counsel, Monsanto Agricultural Company, St. Louis, Mis-
souri; B.A., University of Oklahoma, 1962; J.D., Northwestern University
School of Law, 1965.
** Attorney, Monsanto Agricultural Company; B.A., Douglass Col-
lege, Rutgers University, 1971;J.D., Washington University, 1981.
1. Miller & Young, Biotechnology: A 'Scientific' Term in Name Only,
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Institutes of Health (NIH) Recombinant DNA Advisory
Committee (RAC).' These guidelines specify how research
should be conducted, particularly the degree of care to be
taken to avoid unintentional release from the laboratory of
experimental genetically-engineered organisms. Various
levels of containment practices are required, depending on
the nature of the organism.
I. BENEFITS OF BIOTECHNOLOGY
Despite the concerns expressed early on by scientists, and
the fears which continue to be expressed by critics of biotech-
nology today, the development of the science continues. The
potential benefits to be gained from biotechnology are too
important to be ignored.
Exciting advances in human health care have already
been made by use of this technology. Products of rDNA tech-
nology include interferon, which is used to treat a certain
form of leukemia, human insulin used to treat diabetes, and
human growth hormone used to help children with dwarfism
to grow to normal size. Health care scientists also are using
biotechnology to create new and safer vaccines to prevent
diseases such as AIDS. Biotechnology will enable scientists to
reduce greatly the risks of vaccination by making it possible
to carefully select the genetic portions of the virus which
causes the immune system response and omit that portion of
the genetic material which causes the disease in making the
vaccine. Scientists also are using biotechnology to develop
techniques to diagnose, treat, and prevent genetic diseases
such as Tay Sachs, Huntington's disease, and multiple
sclerosis.
Biotechnology is being applied in agriculture to increase
food production and to improve farming efficiency. Applica-
tions include the development of animal vaccines and drugs
to treat animal diseases. The technology also is being applied
to make growth hormones to help food producing animals to
grow larger and faster, to decrease body fat, and to utilize
feed more efficiently. Several companies are experimenting
with bovine somatotropin, a growth hormone which greatly
increases the feed efficiency of the cow, thus increasing the
2. Notice for Public Comment on Guidelines for Recombinant DNA
Research, 41 Fed. Reg. 27,902 (1976) [hereinafter Guidelines for Recom-
binant DNA Research].
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amount of milk produced without a proportionate intake in
feed.
Scientists are working on adding new genetic traits to
food and feed crops, such as disease resistance, pest resis-
tance, and tolerance to drought, heat and cold. These ad-
vances would reduce the risks faced by farmers by extending
the growing season and making crops less susceptible to vary-
ing weather conditions and disease. It may be possible one
day to grow food crops in Third World countries where they
cannot now be grown and are greatly needed to feed large
populations.
Research is being conducted to genetically engineer mi-
crobes to protect plants from insects, to prevent injury to
plants from frost, and to take nitrogen from the air and con-
vert it to a form which can be used by plants.
Industrial applications of biotechnology include engi-
neering of microbes which will be able to break down indus-
trial waste into components which are not hazardous to
health or the environment.
The economic potential of biotechnology is difficult to
overestimate. Clearly, it will be significant. It can reduce
farming costs through more efficient feed utilization by ani-
mals and the reduced use of fertilizers, herbicides and insecti-
cides. By making farming more efficient, biotechnology can
help American farm products become more competitive in
world markets. Biotechnology can make industry more effi-
cient as well, by providing new, cost effective methods for dis-
posing of industrial wastes and by contributing to the devel-
opment of more efficient manufacturing processes in some
industries. By improving human health, costs of medical care,
and economic losses caused by disease, government and com-
munity health support programs can be dramatically reduced
with a corresponding benefit to all of society.
Recombinant DNA research has been conducted for al-
most a decade now, and the catastrophes feared by some and
predicted by a few have not occurred. Genetically-engineered
organisms have not escaped from the laboratory and caused
epidemics of new diseases nor persisted in the environment
to destroy the ecological balance. Genetic scientists have not
begun to "clone" individuals or eliminate individualism by se-
lectively enhancing or deleting certain genetic traits.
The investigation and development of rDNA technology
has proceeded very cautiously. It is unlikely that any new
technology has ever before been so carefully studied and
evaluated. As scientists have gained more knowledge about
19871
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biotechnology, they have discovered that many concerns
expressed early in the development of the technology are
without scientific basis. As a result, the RAC guidelines have
been relaxed with respect to the number and degree of pre-
cautions and safeguards required for most experiments.
And yet, ethical and safety concerns persist, and govern-
ment regulators, scientists, and members of the public con-
tinue to debate them. This is due in part to legitimate con-
cerns which should be addressed and in part to the fact that
the potential dangers and consequences of rDNA technology
have been intentionally distorted and exaggerated by some
critics and are often misunderstood by the general public.
Critics of biotechnology include the Foundation on Eco-
nomic Trends, the Committee for Responsible Genetics, the
Council on International and Public Affairs, The Humane
Society, and the International Center for Law in Develop-
ment. Perhaps the best known critic of the science is the
founder and president of the Foundation on Economic
Trends (FET), Jeremy Rifkin, a commentator on, and critic
of, the potential social and environmental effects of the de-
velopment and use of biotechnology. Mr. Rifkin and the FET
have filed numerous lawsuits against universities, scientists,
and government agencies, the effect of which has been the
delay of advances in this new area of science. The following
complaint is typical:
Among the concerns of the Foundation are the poten-
tial for a "biohazard" or contamination of the planetary
gene pool resulting from genetic engineering; the ethical,
moral and philosophical implications of artificially con-
trolled biological reproduction; the impact genetic engi-
neering will have on the family and other social institutions;
the legal issues surrounding genetic and biological research;
the effects of low-level radiation and synthetic chemicals on
human chromosomes and reproductive organs; environ-
mental consequences of introducing new genetically modi-
fied life forms; and the economics of bioengineering-who
will reap the benefits and who will pay the costs.
3
Lately, Mr. Rifkin has been unsuccessful in his attempts
to use the judicial system to halt the developments of biotech-
nology. Two recent lawsuits filed by Mr. Rifkin have been
5. Complaint for Declaratory and Injunctive Relief at 4-5, Founda-
tion on Economic Trends v. Thomas, 657 F.Supp. 25 (D.D.C. 1986) (first
amended complaint dismissed).
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dismissed by the courts.' However, there is no doubt that Mr.
Rifkin and his supporters will continue to use the courts to
delay the progress of the science. Most recently, the Founda-
tion on Economic Trends has filed a lawsuit against the De-
partment of Health and Human Services relating to the Food
and Drug Administration's review of bovine somatotropin. s
II. Two BASIC CONCERNS
Two of the most widely debated concerns about rDNA
technology are the potential consequences of deliberate re-
lease of genetically-modified organisms into the environment,
and the effect of such organisms on genetic diversity and bio-
logical integrity of plants and animals, including humans. A
third less dramatic but also widely debated concern is the so-
cial and economic disruption resulting from the development
of the science.
A. Uncontrolled Proliferation
Many genuine concerns have been expressed regarding
the deliberate release of genetically-modified organisms into
the environment. The fear is that the engineered organism
may be more viable than the unengineered organism and
may proliferate and damage or destroy the ecological bal-
ance, or that it may pass on genetic traits such as extraordi-
nary susceptibility to a disease or resistance to a pesticide,
and thus result in the creation of new pests which will spread
disease or proliferate beyond control.
While such an occurrence is theoretically possible, the
risk that it will actually materialize is very small for a number
of reasons. First, the technology itself provides important
safeguards. In classical breeding techniques, where genetic
material from one organism is transferred to another organ-
ism, the breeder cannot always control the outcome. In try-
ing to transfer a single genetic trait, which may be encom-
passed in a single gene, the breeder actually transfers
hundreds or even thousands of genes, and cannot always pre-
dict the outcome of such a transfer. Genetic engineering us-
ing rDNA technology, on the other hand, permits the trans-
fer of a single gene so that only the desired genetic trait is
4. Id., and Foundation on Economic Trends v. Johnson, No. 86-
1956 (D.D.C. 1986) (complaint dismissed Dec. 22, 1986).
5. Foundation on Economic Trends v. Department of Health and
Human Services, No. 87-1009 (D.D.C. filed April 10, 1987).
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transferred. As a result, the nature of the engineered organ-
ism is much more predictable.
The technology also enables scientists to engineer into
the organism traits which will help to prevent proliferation.
The.organisms can be made weak so that they are unable to
survive in the natural environment for more than a very
short period of time. They can be engineered so that they
cannot survive in the human body and thus cannot transmit
disease to people. Genetic traits can be incorporated in such a
way that they cannot be passed on to other organisms. Classi-
cal breeding techniques do not usually permit these charac-
teristics to be incorporated.
The technology also permits the genetically-engineered
organism to be marked, so that it can be detected and de-
stroyed if for some reason the organism appears to present a
danger to health or the environment.
Government agencies will continue to thoroughly regu-
late to prevent harm to health and the environment. Govern-
ment regulators are proceeding carefully and have created a
regulatory system which will govern the development and
testing of all biotechnology-derived products.
The principal federal agencies with authority to regulate
biotechnology are the NIH, the Environmental Protection
Agency (EPA), the United States Department of Agriculture
(USDA), the Food and Drug Administration (FDA), and the
Occupational Safety and Health Administration (OSHA).
Last year, the Office of Science and Technology Policy issued
the Coordinated Framework for the Regulation of Biotech-
nology ("Framework")." The Framework sets out the regula-
tory policy of each of the federal agencies which regulate
biotechnology.
The EPA regulates pesticides and toxic chemicals (de-
fined to include genetically-engineered microorganisms and
to exclude most products regulated by other federal agen-
cies).' The FDA has jurisdiction over food, food additives,
drugs, animal feed additives, animal drugs, medical devices,
and cosmetics. The USDA has authority to regulate plants
and plant products, animal biologics, plant pests, meat and
poultry products, noxious weeds, and the importation and
6. Coordinated Framework for the Regulation of Biotechnology;
Announcement of Policy and Notice for Public Comment, 51 Fed. Reg.
23,302-350 (1986) [hereinafter Framework].
7. Notice for Public Comment on Proposal for a Coordinated
Framework for Regulation of Biotechnology, 49 Fed. Reg. 50,858 (1984).
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interstate movement of animals, plants and seeds. The OSHA
regulates worker health and safety.
The EPA and USDA are the two agencies which will be
primarily responsible for regulating products comprised of
genetically-engineered organisms to be used in the environ-
ment. Both agencies have established regulatory policies
which will require review of these organisms before they are
released into the environment, and have established proce-
dures to fully assess and eliminate or limit the risk which may
be presented.
The EPA has established a two-level reporting system.
The agency will conduct limited review of certain organisms
which, due to their very nature, present a very minimal risk
of creating any adverse effect on health or the environment.
Such organisms are, for example, those formed from genetic
material of very similar organisms and those formed by ge-
netic material from nonpathogenic organisms. 8 Other orga-
nisms will be reviewed more extensively. 9 In the course of
both levels of review, the agency will require extensive green-
house and laboratory tests designed to predict the viability of
the organism, the likelihood of transfer of engineered ge-
netic traits to other organisms, the effect of the engineered
organism on other organisms in the environment (including
insects, aquatic life, animals and plants), and other character-
istics of the organism and the environment into which it will
be released as deemed necessary by the agency. The EPA has
established a Science Advisory Committee for Biotechnology
which will provide peer review of the EPA's decision and will
oversee its biotechnology policies and programs.1" This com-
mittee will be made up of scientific and technical experts who
are qualified to assess the hazards of exposure and the impact
on the ecology.
The USDA has established a system whereby review is
required before a genetically-engineered organism can legally
be released into the environment." Before a release will be
8. "Pathogen" is defined in the Framework as "a virus or microor-
ganism (including its viruses and plasmids, if any) that has the ability to
cause disease in other living organisms (i.e., humans, animals, plants, mi-
croorganisms)." Framework, supra note 6, at 23,307. More simply, a patho-
gen is an organism which causes disease.
9. Notice of Statement of Policy; Microbial Products Subject to the
Federal Insecticide, Fungicide, and Rodenticide Act and the Toxic Sub-
stances Control Act, 51 Fed. Reg. 23,313, 23,320-321 (1986).
10. Id. at 23,318-319.
11. Final Policy Statement for Research and Regulation of Biotech-
19871
JOURNAL OF LAW, ETHICS & PUBLIC POLICY
permitted, the USDA will require laboratory and greenhouse
tests designed to determine information similar to that re-
quired by the EPA. In addition, the USDA has established
guidelines, very similar to NIH/RAC guidelines, to regulate
laboratory and greenhouse research funded by the Depart-
ment, and has expressed the hope that these guidelines will
be voluntarily followed by industry in conducting its own
research."' The USDA also has established the Agricul-
ture Biotechnology Recombinant DNA Advisory Committee
(ABRAC), which will function much like the NIH/RAC to
oversee the implementation of the Department's guidelines.
13
Members of the ABRAC will provide scientific judgments on
the safety of experiments they will review under the guide-
lines.
Government regulation of biotechnology, as currently es-
tablished, is very extensive'and begins at the earliest stage of
product testing and development. It provides for public no-
tice of decisions by the USDA and the EPA, and the regula-
tions of both agencies provide for public participation in the
regulatory decision making process. The regulations of both
agencies also provide for review of agency decisions by ex-
perts qualified to assess the risks presented by the particular
test, experiment, or product.
Each government agency will assess the risk of each test,
experiment, or product, and decide whether it can be con-
ducted or used safely. As when they review traditional prod-
ucts, theagencies use the knowledge and expertise of scien-
tists and other experts along with quantitative risk assessment
techniques, such as mathematical models, to assess the poten-
tial risks of the product.
The agencies with responsibility to regulate biotechno-
logical products plan to create a data base of information
which will eventually enable them to regulate these products
more efficiently as more experience in this area of regulation
is obtained. Even after this data base is established, regula-
tory decisions will be made to a great extent on a case by case
evaluation of the risks presented by each individual product
based on information derived from testing required by the
agency as a prerequisite to approval of the product.
nology Processes and Products, 51 Fed. Reg. 23,336, 23,342 (1986) [here-
inafter Final Policy Statement].
12. Advanced Notice of Proposed USDA Guidelines for Biotechnol-
ogy Research, 51 Fed. Reg. 23,367 (1986).
13. Final Policy Statement, supra note 11, at 23,336-337.
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In addition to safeguards imposed by regulatory require-
ments, industry has voluntarily complied with the NIH/RAC
guidelines since they were first promulgated. One of the re-
quirements in the guidelines is that each organization con-
ducting rDNA research establish an Institutional Biosafety
Committee (IBC) to be composed of experts from within the
organization, as well as outside experts who are not otherwise
affiliated with the company and who are qualified to review
the safety and ethics of each rDNA experiment or test." The
role of the IBC is important, because it provides for review of
research programs by experts who have appropriate scientific
knowledge and ability to objectively evaluate the safety of the
experiment. IBC's also often include members with expertise
and particular interest in protection of the environment and
community standards. The IBC is designed to provide a thor-
ough, multi-faceted review."
Due to all of the safeguards that can be engineered into
the organism itself, as well as the reviews conducted by the
IBC and regulatory agencies, it is nearly impossible to con-
ceive of an experiment that can go so wildly astray that cata-
strophic, or, for that matter, even lesser hazardous effects can
occur which would result in harm to health or the environ-
ment.
B. Genetic Diversity
Another widely discussed perceived danger of rDNA
technology is the effect on genetic diversity. The issues pre-
sented by this concern involve both safety and ethical con-
siderations.
Critics of biotechnology express the fear that through
engineering many genetic traits will eventually be eliminated
from all species, thus reducing the genetic diversity of plants
and animals. Some critics foresee certain catastrophe as the
world is left with a small genetic pool of living organisms
which succumb to some disease epidemic or insect plague.
Actually, the possibility of a disaster like this is more
likely without the development of rDNA technology. For ex-
ample, when many farmers grow a single strain of crop which
is particularly susceptible to a disease, there is a realistic risk
that the disease may take hold and destroy all of the crops in
14. Guidelines for Recombinant DNA Research, supra note 2, at
27,920-921.
15. Guidelines for Research Involving Recombinant DNA Molecules,
49 Fed. Reg. 46,266, 46,270 (1984).
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a large geographic area. The fact is, however, that rDNA
technology can reduce or even eliminate this risk. By reduc-
ing the time needed to create new strains with characteristics
such as resistance to certain diseases, and by making it possi-
ble to combine genetic traits from sexually incompatible spe-
cies, biotechnology can be used to produce a wide diversity of
crop varieties which can withstand not only disease, but also
invasions by insects, drought, and extremes in temperature.
The potential that the technology will make it possible to
overcome natural breeding barriers and transfer genes be-
tween species also will make it possible to increase genetic di-
versity. For example, someday it may be possible to transfer
genes from bacteria into plants. A useful application of this
development would be to transfer nitrogen fixation genes
from bacteria to plants to reduce the need for nitrogen fertil-
izers, thus reducing the cost and increasing the efficiency of
farming operations.
The very notion of transferring genes between species
opens up many possibilities which raise obvious ethical con-
cerns. Some critics fear that it is only a matter of time until
human and animal traits will be transferred between species
indiscriminately.
Ethical issues also are raised by so-called "human gene
therapy," or the ability to eliminate or modify human genetic
traits. There are really two categories of human gene ther-
apy. Somatic therapy is the elimination or modification of the
genes of the affected individual for the purpose of curing or
preventing genetic diseases such as Downs Syndrome, muscu-
lar dystrophy, and Tay Sachs disease. The genetic change
does not affect future generations. The other category of
human gene therapy is germline therapy, which involves
modification of the genetic pattern. Such modification would
be passed on to future generations.
Critics fear that human gene therapy will be used to
eliminate genetic traits and predetermine physical and other
characteristics of future generations. They predict it will be
used to standardize characteristics such as height, eye color
and intelligence.
There are, no doubt, very legitimate questions about the
extent to which gene transfer between species and human
gene therapy should be practiced, such as which traits should
be transferred between species, which traits are "bad" and
should be eliminated through gene therapy, and who should
decide. It is equally true that there are concerns which have
been voiced by critics which are not valid. For example, crit-
[Vol. 3
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ics have alleged that the transfer of human genes into ani-
mals is cruel and immoral because it somehow changes the
nature of the animal. This is not a valid concern. A single
gene does not determine the nature of an organism. The in-
sertion of a human gene into an animal does not impart
human characteristics to that animal.
Legitimate safety and ethical questions should and have
been addressed.16 Clearly the answer is not to stop the devel-
opment of technology. The advancement of any science or
technology poses many ethical questions which must be ad-
dressed by society. Advancement in medical technology, for
example, has raised issues about the responsibility of physi-
cians to take extraordinary measures to sustain life, and has
created the question of the "right to die." One would not
suggest that because of these issues the development of medi-
cal technology should cease. Rather, society must assess the
issues and develop ethical codes and social institutions to ad-
dress the problem and form a consensus about how it should
be resolved. The same is true of the issues raised by biotech-
nology. In debating these issues, it is important that the risks
presented be accurately defined and scientifically understood
and that scientifically invalid criticisms and concerns be rec-
ognized and discounted. In order for legitimate ethical con-
siderations to be rationally discussed and resolved, it is essen-
tial that unscientific rhetoric be separated from the facts and
that science not be confused with ideology.
III. SOCIAL AND ECONOMIC DISRUPTION
Critics of biotechnology have predicted significant eco-
nomic and social disruption as a result of some of the prod-
ucts derived from biotechnology which will soon be available.
For example, such criticism has been directed at bovine so-
matotropin (BST), which research shows will be useful to in-
crease milk production of dairy cows while reducing intake of
feed per gallon of milk produced. Critics have predicted
16. In 1982 a Presidential Commission undertook to study the mat-
ter PRESIDENT'S COMMISSION FOR THE STUDY OF ETHICAL PROBLEMS IN
MEDICINE AND BIOMEDICAL AND BEHAVIORAL RESEARCH, SPLICING LIFE: A RE-
PORT ON THE SOCIAL AND ETHICAL ISSUES OF GENETIC ENGINEERING WITH
HMAN BEINGS (1982). This Report was the subject of Congressional hear-
ings. e.g., Human Genetic Engineering: Hearings Before the Subcommittee on In-
vestigations and Oversight of the House Comm. on Science and Technology, 97th
Cong 2nd Sess. (1982) See also Singer. Genetics and the Law. A Scientist's
t'ie, 'k YAL lA5% & POL'y REv .29-330 (1985)
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that BST will cause increased milk production, requiring in-
creased government support of the dairy industry and result-
ing in smaller dairy farmers going out of business.
In fact, BST should not have such an impact. It is un-
likely that it will be used to produce more milk, but rather to
produce the same amount of milk more efficiently, with
fewer cows. The size of the farm should not affect the
farmer's ability to use BST to increase the efficiency of his
operation.
While the criticism leveled at BST is not legitimate, it
cannot be denied that the development of any new technol-
ogy is likely to change social and economic patterns to some
extent. It will be important to anticipate the likely changes
and prepare for them, but, as in the case of gene therapy, the
answer is not to prohibit development of the technology.
IV. RISKS OF OVER-REGULATION
No one with an understanding of biotechnology will seri-
ously argue that there are not important questions of safety
and ethics which must be addressed. In some cases, regula-
tion will be required. As has already been discussed, mecha-
nisms are being developed and some are already in place, to
address ethical considerations and to insure that tests and ex-
periments involving biotechnololy will be reviewed to pre-
vent harm to health and the environment. While there is no
doubt that there are issues that remain to be resolved, there
is a real danger to the further development of the industry if
they are not approached rationally.
Biotechnology presently is being regulated to a much
greater extent t an are most other industrial and scientific
endeavors. Under the regulations published in the Frame-
work, regulatory oversight begins much earlier in the process
of product development than is true for most other products,
such as pesticides and plant hybrids, manufactured or created
by more traditional technologies. The possibility of over-reg-
ulation, brought about to a great extent by the failure of reg-
ulators and the public to understand the science, which is in
part due to the rhetoric of many of its critics, may eventually
stifle further development. The industry already is realizing
that the extent of regulation of biotechnology results in the
development of biotechnologically-derived products being
much more time consuming and expensive than development
of other products. Industry is having to face the fact that this
may result in inability or unwillingness to develop some
[Vol. 3
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potentially useful and beneficial products. Examples are vac-
cines and drugs which would be used to treat rare diseases
and organisms which could be engineered to control rare but
troublesome pests. Since the market for such products is rela-
tively small, it is unlikely that industry would be able to re-
cover the very large development, including regulatory,
costs.
The high cost of development is only one problem which
results from overly cautious regulation. Another is regulatory
delay, which, though inherent in the regulatory process, may
be prohibitive in the case of biotechnology. At the present
time, the United States is far ahead of other countries in the
development of biotechnology. But this lead will be lost if ex-
pense and delays associated with the development of new bio-
technology products in the U.S. are excessive. The result will
be that foreign companies will usurp the leadership position
now enjoyed by U.S. industry. The way to prevent this loss is
to approach regulation of biotechnology rationally, with a
sound understanling of the scientific principles on which it is
based, so that it is regulated adequately but not excessively.
The science of biotechnology holds the key to improving
the quality of human life more dramatically than any previ-
ous scientific endeavor. This quest will continue. If the sci-
ence is to be allowed to develop to its full potential, the pub-
lic and the government must not be misled by ideologists
predicting dire consequences which is not based on an under-
standing of the science. This new science holds the promise
of eradicating many of society's worst problems, such as can-
cer, AIDS, and starvation. Failure to develop this technology
will allow disease and hunger to continue when the science to
alleviate much of it is at hand.
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